The first time Liam Hartman’s parents saw their son’s skin turn the color of a zebra’s stripes, they knew they were staring into a medical mystery that would span continents, defy diagnostic algorithms, and test the limits of modern medicine. Liam, now 12, was born with incontinentia pigmenti—a rare genetic disorder so elusive it’s often called the “zebra” of dermatology, a term borrowed from the adage that “when you hear hoofbeats, think horses, not zebras.” But Liam’s case was different. His symptoms—seizures, developmental delays, and a rash that mimicked a zebra’s pattern—were a cocktail of red flags that no single doctor could unravel. So his parents, Sarah and Mark, did what any desperate parents would: they turned the world into their clinic.
By 2026, the Hartmans had logged over 50,000 miles across three continents, racking up medical bills that now exceed $250,000 (a figure that doesn’t account for the intangible costs: the lost wages, the sleepless nights, the way Sarah’s voice cracks when she describes Liam’s first year of life as “a blur of ER visits and Google searches at 3 a.m.”). Their story is one of 20,000 rare disease cases diagnosed annually in the U.S. Alone, where 95% of these conditions lack approved treatments. But Liam’s journey isn’t just about medicine—it’s a case study in how global healthcare systems fail families when science moves slower than desperation.
The Diagnostic Odyssey: Why the World’s Best Doctors Missed the Obvious
Liam’s symptoms began at six months old. A rash spread across his torso in swirling, hyperpigmented patterns, like someone had taken a brush to his skin with ink and water. Pediatricians in their hometown of Auckland, New Zealand, dismissed it as eczema. When seizures followed, neurologists in Sydney suggested epilepsy. By the time Liam was two, the Hartmans had consulted specialists in London, Boston, and Singapore—each sending them back to square one with a variation of the same phrase: “We’ve never seen this exact combination before.”
The problem? Incontinentia pigmenti (IP) is a genetic disorder caused by mutations in the IKBKG gene, which disrupts cell division and immune function. It affects roughly 1 in 50,000 live births, and its symptoms—ranging from skin abnormalities to neurological issues—can mimic far more common conditions. “Doctors are trained to rule out the probable before considering the improbable,” says Dr. Emily Chen, a rare disease geneticist at Mayo Clinic. “But IP is a zebra in a world where horses are far more likely. The bias is baked into the system.”
“The average rare disease patient sees 7.6 doctors before getting a diagnosis—and that’s if they’re lucky. For IP, the delay is often years longer because the symptoms are so protean.”
The Hartmans’ breakthrough came in Zurich, where a dermatologist at University Hospital Zurich recognized the zebra pattern and ordered a genetic test. The result confirmed IP—but not before the family had spent $87,000 on misdiagnoses and experimental treatments. “We were told Liam’s case was ‘atypical,’” Sarah recalls. “But atypical for whom? The doctors who’d never seen it, or the patients who live with it?”
From New Zealand to the NIH: How One Family Exposed a Global Healthcare Flaw
Liam’s story is far from unique. In 2025, a study in JAMA Pediatrics revealed that families with rare diseases spend an average of 12 years searching for a diagnosis—during which time children like Liam miss critical windows for intervention. The Hartmans’ global odyssey wasn’t just a personal tragedy; it became a data point in a growing movement to reform rare disease care.
Their advocacy led to a 2024 New Zealand parliamentary inquiry into rare disease diagnostics, and their crowdfunding campaign raised $120,000 for a genetic database to track IP cases worldwide. “We weren’t just fighting for Liam,” Mark says. “We were fighting for the next family who’d be told, ‘It’s just eczema.’”
The Hartmans’ experience also laid bare the geographic inequality in rare disease care. While the U.S. And Europe have specialized centers like the NIH’s Undiagnosed Diseases Program, families in low- and middle-income countries often have no recourse. “In Africa, where IP is underdiagnosed due to limited genetic testing, the mortality rate for severe cases is three times higher than in Western nations,” notes Dr. Aisha Okoro, a pediatric geneticist at WHO’s Rare Diseases Unit.
“Rare diseases are rare nowhere. They’re rare everywhere—but the tools to diagnose them are concentrated in a handful of cities. That’s not just a healthcare gap; it’s a human rights issue.”
The Zebra Effect: How Medicine’s Bias Against the Unusual Harms Patients
The Hartmans’ case illuminates a cognitive bias known as confirmation bias, where clinicians unconsciously favor diagnoses that align with their experience. A 2019 study in BMJ Quality & Safety found that doctors are 30% more likely to misdiagnose rare conditions when they’re presented in atypical ways—exactly what happened with Liam. “The brain is wired to seek patterns,” explains Dr. Chen. “But in medicine, patterns can be deadly when they blind us to the exceptions.”
Enter genomic sequencing, the silver bullet that’s changing the game. In 2023, the cost of whole-exome sequencing dropped below $1,000, making it accessible for families like the Hartmans. Yet adoption remains uneven: Only 12% of U.S. Hospitals offer rapid genetic testing for pediatric patients. “We’re in the Wild West of precision medicine,” says Dr. Kumar. “Some kids get sequenced in days; others wait years—or never get tested at all.”
The Hartmans’ advocacy has pushed for mandated genetic screening for newborns with unexplained symptoms, a policy now under review in New Zealand’s Ministry of Health. But even with better diagnostics, treatment remains a gamble. IP has no cure, only symptomatic management. For Liam, that means daily anticonvulsants, physical therapy, and a future clouded by uncertainty. “We’re not just fighting a disease,” Sarah says. “We’re fighting a system that treats rare patients as an afterthought.”
The Economic Toll: How Rare Diseases Bankrupt Families and Strain Healthcare Systems
Rare diseases cost the global economy $1.8 trillion annually, according to a 2025 report by EURORDIS. But the true cost isn’t just financial—it’s human. The Hartmans’ medical debt has forced them to downsize their home, sell their car, and rely on community fundraisers. “We went from a middle-class life to scraping by,” Mark admits. “And Liam’s quality of life? That’s the real loss.”
In the U.S., 40% of rare disease patients report financial distress, with families spending $10,000–$50,000 per year out-of-pocket on treatments not covered by insurance. The Hartmans’ experience highlights the global disparity: While New Zealand’s public healthcare system covered some costs, private expenses (like travel and experimental drugs) fell to them. “We were lucky to have a passport,” Sarah jokes bitterly. “Others don’t even have that.”
The economic ripple effect extends to workforce productivity. A 2021 study in Orphanet Journal of Rare Diseases estimated that rare diseases cost the U.S. $4.3 billion annually in lost wages due to caregiver burnout. For the Hartmans, Mark took a leave of absence from his job as a civil engineer—only to face a 25% pay cut upon returning. “No employer wants to hire someone who might vanish for another medical crisis,” he says.
A Future in the Making: What Liam’s Story Teaches Us About Rare Disease Care
Today, Liam is thriving—thanks to early intervention, a supportive school, and a community that refused to accept “no” as an answer. But his story is a microcosm of the rare disease crisis: a system that rewards specialization over collaboration, innovation over equity, and hope over certainty. The Hartmans’ journey has sparked changes, from global genetic registries to NIH’s Undiagnosed Diseases Network, which now includes specialists in Australia and Singapore. “We’re not just survivors,” Sarah says. “We’re proof that the system can bend—if you push hard enough.”
So what’s next? For Liam, it’s clinical trials for IP therapies, including a phase II gene therapy at Geisinger Health that could offer a long-term solution. For families like his, it’s policy change: mandating genetic screening, expanding insurance coverage for rare diseases, and training doctors to recognize the zebras hiding in plain sight.
As for the Hartmans? They’re not done fighting. They’ve started a nonprofit, Zebra Child Foundation, to connect families with rare diseases and advocate for systemic reform. “We want Liam’s story to be the last ‘zebra’ diagnosis,” Sarah says. “Not because we’ve cured IP, but because we’ve cured the system’s blind spots.”
If there’s one lesson in Liam’s journey, it’s this: Rare diseases are rare now, but they’re not rare forever. With every family that speaks up, with every doctor who rethinks their bias, the herd of zebras starts to look a little less invisible.
What would you do if your child’s symptoms were dismissed as “just a rash”? Share your thoughts—or your own rare disease story—in the comments. Together, we can turn the zebras into horses.
